Skip to main content

We use cookies

Necessary cookies

Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.

Analytics cookies

Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.

Switch analytics

ON OFF

Clarity

Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.

Switch clarity

ON OFF

Privacy policy

Study
Research
Explore
Connect

Study
Research
Explore
Connect

College of Science & Engineering

News

News archive

Keltic Pharma Therapeutics awarded $1.3 million from Gates Foundation for malaria drug discovery programme

Published: 8 January 2026

Keltic Pharma Therapeutics, a UofG spin-out, has been awarded £1.15 million in new funding from the Gates Foundation to accelerate its ground-breaking malaria drug discovery programme. Founded by Professors Andrew Tobin, Graeme Milligan, and Andrew Jamieson, together with an experienced commercial and translational leadership team, Keltic combines world-class expertise in GPCR pharmacology, medicinal chemistry and AI-enabled molecular design.

Full story here

First published: 8 January 2026

<< News

<< previous story

in this issue

next story >>

Back to the top